Stockreport

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab [Yahoo! Finance]

MoonLake Immunotherapeutics - Class A Ordinary Shares  (MLTX) 
PDF New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LED [Read more]